Norris Medicines Limited (BOM:524414)
India · Delayed Price · Currency is INR 13.56
+0.04 (0.30%)
At close: Jun 17, 2026
Norris Medicines Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 81.32 | 58.2 | 56.36 | 83.59 | 94.38 | |
Revenue Growth (YoY) | 39.72% | 3.28% | -32.58% | -11.44% | -22.96% |
Cost of Revenue | 43.05 | 35.08 | 26.99 | 35.23 | 57.25 |
Gross Profit | 38.27 | 23.12 | 29.36 | 48.36 | 37.13 |
Selling, General & Admin | 16.69 | 14.13 | 18.21 | 22.98 | 23.38 |
Other Operating Expenses | 14.48 | 11.2 | 12.94 | 16.13 | 14.39 |
Operating Expenses | 36.08 | 30.7 | 36.86 | 45.4 | 44.33 |
Operating Income | 2.19 | -7.58 | -7.5 | 2.95 | -7.2 |
Interest Expense | -5 | -4.21 | -3.66 | -14.89 | -14.73 |
Interest & Investment Income | - | 0.18 | 0.18 | 0.12 | 0.12 |
Currency Exchange Gain (Loss) | - | 0.01 | 0.04 | - | 0.05 |
Other Non Operating Income (Expenses) | - | -0.19 | -0.04 | -0.12 | -0.09 |
EBT Excluding Unusual Items | -2.81 | -11.78 | -10.98 | -11.93 | -21.85 |
Pretax Income | -2.81 | -11.78 | -10.98 | -11.93 | -21.85 |
Income Tax Expense | - | 0.59 | 0.89 | 5.56 | 10.79 |
Net Income | -2.81 | -12.37 | -11.87 | -17.49 | -32.63 |
Net Income to Common | -2.81 | -12.37 | -11.87 | -17.49 | -32.63 |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 |
Shares Change (YoY) | 0.21% | - | - | - | - |
EPS (Basic) | -0.28 | -1.24 | -1.19 | -1.75 | -3.26 |
EPS (Diluted) | -0.28 | -1.24 | -1.19 | -1.75 | -3.26 |
Free Cash Flow | 5.68 | 4.91 | 1.69 | 11.7 | -10.65 |
Free Cash Flow Per Share | 0.57 | 0.49 | 0.17 | 1.17 | -1.06 |
Gross Margin | 47.07% | 39.72% | 52.10% | 57.86% | 39.34% |
Operating Margin | 2.70% | -13.03% | -13.31% | 3.54% | -7.63% |
Profit Margin | -3.45% | -21.26% | -21.06% | -20.93% | -34.58% |
Free Cash Flow Margin | 6.98% | 8.44% | 2.99% | 13.99% | -11.28% |
EBITDA | 7.1 | -2.21 | -1.78 | 9.25 | -0.63 |
EBITDA Margin | 8.73% | -3.80% | -3.17% | 11.07% | -0.67% |
D&A For EBITDA | 4.91 | 5.37 | 5.71 | 6.3 | 6.57 |
EBIT | 2.19 | -7.58 | -7.5 | 2.95 | -7.2 |
EBIT Margin | 2.70% | -13.03% | -13.31% | 3.54% | -7.63% |
Revenue as Reported | 81.77 | 58.82 | 56.64 | 83.73 | 94.64 |
Advertising Expenses | - | 0.06 | - | -0.01 | 0.08 |